Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $2.00 at Cantor Fitzgerald

Lucid Diagnostics (NASDAQ:LUCD) had its price objective lowered by Cantor Fitzgerald from $3.00 to $2.00 in a research note published on Friday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

LUCD has been the subject of a number of other research reports. Needham & Company LLC restated a “buy” rating and set a $2.50 price objective on shares of Lucid Diagnostics in a research report on Thursday, November 14th. Canaccord Genuity Group reissued a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a research note on Thursday, November 14th. Canaccord Genuity Group raised Lucid Diagnostics to a “strong-buy” rating in a research note on Tuesday, August 13th. Finally, Ascendiant Capital Markets lowered their target price on Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating for the company in a research report on Tuesday, September 10th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $3.69.

Lucid Diagnostics Stock Performance

Shares of NASDAQ:LUCD opened at $0.95 on Friday. The firm has a market cap of $56.37 million, a price-to-earnings ratio of -0.83 and a beta of 1.41. The firm has a fifty day moving average price of $0.87 and a 200 day moving average price of $0.85. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.58.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lucid Diagnostics stock. Virtu Financial LLC raised its stake in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,671 shares of the company’s stock after purchasing an additional 13,835 shares during the period. Virtu Financial LLC owned 0.07% of Lucid Diagnostics worth $28,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 74.01% of the stock is currently owned by institutional investors and hedge funds.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.